Fed. Circ. Backs Eli Lilly Alimta Patent Win Under Akamai
The Federal Circuit on Thursday upheld an order barring Teva from launching a generic version of Eli Lilly's lung cancer drug Alimta, ruling that the generics maker is liable for inducing...To view the full article, register now.
Already a subscriber? Click here to view full article